Last Updated: November 13, 2026

Specgx Llc Company Profile

« Back to Dashboard

What is the competitive landscape for SPECGX LLC

SPECGX LLC has sixty-four approved drugs.

Summary for Specgx Llc

US Patents:	0
Tradenames:	50
Ingredients:	34
NDAs:	64

Drugs and US Patents for Specgx Llc

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Specgx Llc	ROXICODONE	oxycodone hydrochloride	TABLET;ORAL	021011-003	May 15, 2009	AB	RX	Yes	No		⤷ Start Trial				⤷ Start Trial
Specgx Llc	METHYLIN ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	075629-001	May 9, 2000	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
Specgx Llc	PAMELOR	nortriptyline hydrochloride	CAPSULE;ORAL	018013-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
Specgx Llc	LISDEXAMFETAMINE DIMESYLATE	lisdexamfetamine dimesylate	TABLET, CHEWABLE;ORAL	218850-006	Dec 17, 2024	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
Specgx Llc	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	040440-004	Oct 7, 2003	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
Specgx Llc	OXYCODONE HYDROCHLORIDE	oxycodone hydrochloride	TABLET;ORAL	076758-004	Oct 12, 2021	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Specgx Llc

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Specgx Llc	RESTORIL	temazepam	CAPSULE;ORAL	018163-003	Oct 25, 1991	5,326,758	⤷ Start Trial
Specgx Llc	PAMELOR	nortriptyline hydrochloride	CAPSULE;ORAL	018013-001	Approved Prior to Jan 1, 1982	3,922,305	⤷ Start Trial
Specgx Llc	PAMELOR	nortriptyline hydrochloride	CAPSULE;ORAL	018013-003	Approved Prior to Jan 1, 1982	3,922,305	⤷ Start Trial
Specgx Llc	EXALGO	hydromorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021217-003	Mar 1, 2010	5,914,131	⤷ Start Trial
Specgx Llc	PAMELOR	nortriptyline hydrochloride	SOLUTION;ORAL	018012-001	Approved Prior to Jan 1, 1982	3,922,305	⤷ Start Trial
Specgx Llc	EXALGO	hydromorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021217-001	Mar 1, 2010	5,914,131	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for SPECGX LLC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Oral Solution	5 mg/5 mL and 10 mg/5 mL	➤ Subscribe	2010-04-13

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.